DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
Regulation of Survival by IKK(epsilon) in Inflammatory Breast Cancer Involves EpCAM
Annual rept. 1 Dec 2012-30 Nov 2013
WASHINGTON UNIV ST LOUIS MO
Pagination or Media Count:
Although triple negative breast cancers TNBC consistently lack hormone receptor expression and ERBB2 amplification, several lines of evidence suggest that these cancers are heterogeneous. Here we find that aberrant expression of the I B kinase IKK related-kinase IKK drives a specific subset of TNBC that are maintained by an autocrine cytokine circuit involving JAKSTAT pathway activation. We identify CYT387 as a novel potent inhibitor of IKK and JAK signaling that disrupts this circuit and preferentially impairs the proliferation of IKK -driven breast cancer cells in vitro. CYT387 treatment inhibits both NF- B and STAT activation and disrupts expression of the pro-tumorigenic cytokines CCL5 and IL-6 in these breast cancer cells. Interruption of cytokine signaling by CYT387 in vivo impairs the growth of an IKK -driven TNBC cell line and patient-derived xenografts. These findings elucidate a specific immune-driven subtype of TNBC that is sensitive to combined IKK and JAK inhibition.
APPROVED FOR PUBLIC RELEASE